Viridian Therapeutics, Inc./DE License and Services Revenue (Deprecated 2018-01-31)
Viridian Therapeutics, Inc./DE (VRDN) reported License and Services Revenue (Deprecated 2018-01-31) of $4.76 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2018-05-09
- Viridian Therapeutics, Inc./DE license and services revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $4.76M, a 47460.00% increase year-over-year.
- Viridian Therapeutics, Inc./DE license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.11M, a 230.15% increase year-over-year.
- Viridian Therapeutics, Inc./DE license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.49M, a 108.81% increase year-over-year.
- Viridian Therapeutics, Inc./DE license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $488.00K, a 42.38% decline year-over-year.
- Viridian Therapeutics, Inc./DE license and services revenue (deprecated 2018-01-31) for fiscal 2017 was $3.10M, a 10.06% increase from fiscal 2016.
- Viridian Therapeutics, Inc./DE license and services revenue (deprecated 2018-01-31) for fiscal 2016 was $2.81M.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 3 month | License and Services Revenue (Deprecated 2018-01-31) 6 month | License and Services Revenue (Deprecated 2018-01-31) 9 month | License and Services Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $4.76M 10-Q · filed 2018-05-09 | $5.86M derived: sum of 2 quarters · filed 2018-05-09 | $7.36M derived: sum of 3 quarters · filed 2018-05-09 | $7.84M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $2.60M derived: sum of 2 quarters · filed 2018-03-15 | $3.09M derived: sum of 3 quarters · filed 2018-03-15 | $3.10M 10-K · filed 2018-03-15 |
| 2017-09-30 | $1.49M 10-Q · filed 2017-11-09 | $1.98M derived: sum of 2 quarters · filed 2017-11-09 | $1.99M 10-Q · filed 2017-11-09 | $2.33M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-06-30 | $488.00K 10-Q · filed 2017-08-11 | $498.00K 10-Q · filed 2017-08-11 | $833.00K derived: sum of 3 quarters · filed 2018-05-09 | $1.55M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-03-31 | $10.00K 10-Q · filed 2018-05-09 | $345.00K derived: sum of 2 quarters · filed 2018-05-09 | $1.06M derived: sum of 3 quarters · filed 2018-05-09 | $1.91M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $335.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $1.05M derived: sum of 2 quarters · filed 2018-03-15 | $1.90M derived: sum of 3 quarters · filed 2018-03-15 | $2.81M 10-K · filed 2018-03-15 |
| 2016-09-30 | $715.00K 10-Q · filed 2017-11-09 | $1.56M derived: sum of 2 quarters · filed 2017-11-09 | $2.48M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $847.00K 10-Q · filed 2017-08-11 | $1.76M 10-Q · filed 2017-08-11 | ||
| 2016-03-31 | $917.00K 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |